Entry-competent-replication-abortive African horse sickness virus strains elicit robust immunity in ponies against all serotypes.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
27 05 2021
Historique:
received: 10 12 2020
revised: 19 02 2021
accepted: 18 04 2021
pubmed: 8 5 2021
medline: 28 5 2021
entrez: 7 5 2021
Statut: ppublish

Résumé

African horse sickness virus (AHSV) is an Orbivirus within the Reoviridae family, spread by Culicoides species of midges, which infects equids with high mortality, particularly in horses and has a considerable impact on the equine industry. In order to control the disease, we previously described Entry Competent Replication Abortive (ECRA) virus strains for each of the nine distinct AHSV serotypes and demonstrated their potential as vaccines, first in type I interferon receptor (IFNAR-/-) knockout mice, and then in ponies. In this report we have investigated whether or not a combination ECRA vaccine comprising nine vaccine strains as two different cocktails is as efficient in ponies and the duration of the immunity triggered by ECRA vaccines. In one study, a group of ponies were vaccinated with a cocktail of 4 vaccine strains, followed by a vaccination of the remaining 5 vaccine strains, mimicking the current live attenuated vaccine regimen. In the second study, ponies were vaccinated with a single ECRA-AHSV strain and monitored for 6 months. The first group of ponies developed neutralising antibody responses against all 9 serotypes, indicating that no cross-serotype interference occurred, while the second group developed robust neutralising antibody responses against the single serotype that were sustained at the same level throughout a 6-month study. The results support our previous data and further validate ECRA vaccines as a safe and efficacious replacement of current live vaccines.

Identifiants

pubmed: 33958224
pii: S0264-410X(21)00481-3
doi: 10.1016/j.vaccine.2021.04.034
pmc: PMC8158431
pii:
doi:

Substances chimiques

Vaccines, Attenuated 0
Viral Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3161-3168

Subventions

Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/F02049X/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/R005567/1
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Rev Sci Tech. 2015 Aug;34(2):315-27
pubmed: 26601437
Vet Res. 2004 Jul-Aug;35(4):445-66
pubmed: 15236676
Emerg Infect Dis. 2014 Dec;20(12):2123-5
pubmed: 25418049
Vaccine. 2020 Oct 21;38(45):7108-7117
pubmed: 32921506
Equine Vet J. 2013 Jan;45(1):117-9
pubmed: 22612775
J Virol. 2013 Sep;87(17):9856-64
pubmed: 23824810
Emerg Infect Dis. 2016 Dec;22(12):2087-2096
pubmed: 27442883
Vaccine. 2014 Sep 3;32(39):4932-7
pubmed: 25045805
J Pharm Pharmacol. 2015 Mar;67(3):426-49
pubmed: 25496339
J Virol. 2016 Jul 27;90(16):7405-7414
pubmed: 27279609
BMC Vet Res. 2020 Sep 1;16(1):322
pubmed: 32873300
Viruses. 2019 Sep 11;11(9):
pubmed: 31514299
J Gen Virol. 1996 Sep;77 ( Pt 9):2053-7
pubmed: 8811002
J Virol. 2011 Oct;85(19):10213-21
pubmed: 21795358
Vaccine. 2017 Jul 24;35(33):4262-4269
pubmed: 28625521
J Virol. 2016 Dec 16;91(1):
pubmed: 27795442
Vaccine. 2002 Jan 15;20(7-8):1079-88
pubmed: 11803068
Virology. 1996 Feb 1;216(1):1-11
pubmed: 8614976
J Virol. 2015 Sep;89(17):8764-72
pubmed: 26063433
Virology. 2008 Aug 1;377(2):308-18
pubmed: 18570969
Vaccine. 2014 Jun 17;32(29):3670-4
pubmed: 24837765
Epidemiol Infect. 2012 Mar;140(3):462-5
pubmed: 21733265

Auteurs

Edward Sullivan (E)

Department of Infection Biology, Faculty of Infectious and Tropical Disease, London School of Hygiene and Tropical Medicine, United Kingdom.

Sylvie Lecollinet (S)

Université Paris-Est ANSES Alfort, UMR 1161 Virologie ANSES, INRA, ENVA, Maisons-Alfort, France.

Adeline Kerviel (A)

Department of Infection Biology, Faculty of Infectious and Tropical Disease, London School of Hygiene and Tropical Medicine, United Kingdom.

Erika Hue (E)

LABÉO Frank Duncombe, 14280 Saint-Contest, France; BIOTARGEN, Normandie Univ, UNICAEN, 14000 Caen, France.

Stéphane Pronost (S)

LABÉO Frank Duncombe, 14280 Saint-Contest, France; BIOTARGEN, Normandie Univ, UNICAEN, 14000 Caen, France.

Cécile Beck (C)

Université Paris-Est ANSES Alfort, UMR 1161 Virologie ANSES, INRA, ENVA, Maisons-Alfort, France.

Marine Dumarest (M)

Université Paris-Est ANSES Alfort, UMR 1161 Virologie ANSES, INRA, ENVA, Maisons-Alfort, France.

Stephan Zientara (S)

Université Paris-Est ANSES Alfort, UMR 1161 Virologie ANSES, INRA, ENVA, Maisons-Alfort, France.

Polly Roy (P)

Department of Infection Biology, Faculty of Infectious and Tropical Disease, London School of Hygiene and Tropical Medicine, United Kingdom. Electronic address: polly.roy@lshtm.ac.uk.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH